Human Embryonic Stem Cells Market, By Product (Regenerative Medicine, Stem Cell Biology Research, Tissue Engineering, and Toxicology Testing) and By Geography (North America, Europe, Asia Pacific, and Rest of the World) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Oct 2022

Code : CMI5275

Pages :170

Formats :

Excel and PDF

Industry : Biotechnology

Leading Companies

Global Human Embryonic Stem Cells Market: Key Developments

In July 2020, Thermo Fisher Scientific Inc. and QIAGEN N.V. entered into an amendment to their acquisition agreement under which Thermo Fisher has commenced a tender offer to acquire all of the ordinary shares of QIAGEN.

In January 2020, Astellas Pharma Inc. and Adaptimmune Therapeutics Plc. entered into a co-development and co-commercialization agreement to bring new stem-cell derived allogeneic T-cell therapies to people with cancer.

Global Human Embryonic Stem Cells Market: Key Companies Insights

The global human embryonic stem cells market is highly competitive. This is attributed to the increase in prevalence of cardiac and malignant diseases, as a result, players in the market are focusing on launching novel products in the market.

Some of the key players in the global human embryonic stem cells market are Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc., among others.